Video: How Superbugs Get Started.
A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening right now...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...
CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).
INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review
Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40 Alpha Pro Tech, Ltd. (NYSE: APT) $6.00AstraZeneca plc (NYSE: AZN) $49BioCryst Pharmaceuticals, Inc.'s (NASDAQ: BCRX) $2.80 Cerus Corporation (NASDAQ: CERS)...
New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.
Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the Biotech Stock...
Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.
https://youtu.be/hnqFdKSG6-A
Auris all over the room, even on the ceiling?.
https://youtu.be/ypyNoM5z40s
Are hospitals keeping real-time infection status a secret?
https://www.youtube.com/watch?v=IOX3JdLvm1Y
ARTICLES:
A Mysterious Infection, Spanning the Globe in a Climate...
Dyadic (DYAI) Highlights.
"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Adding Citius (CTXR) $0.55 to Watch List.
Best Presentation at Dawson James Conference.
We attended the Dawson James Conference on October 29th, which had over 20 medtech and biotech companies. The two...
Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Analyst Take: "Potential to be Revolutionary. Dyadic’s C1 shows potential in...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
INVESTOR PRESENTATION
LONGER TERM CHART
Client, see published reports for disclosure and disclaimer details.
Latest article
Inbcubator Society Pass (SOPA), Expanding into Private AI Software Companies, and Private AI Data...
Society Pass was riding high earlier this year, after announcing they successfully spun off one of its holding companies, into a publicly traded entity,...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
Biotech Stock Review. All Ideas, 2020-2025.
Top Ideas as Defined by 'Peak Gain' from 2020 to 2025
This is every stock we've covered and added to the Watch List during that...
